A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial-Reference-Cited by-同舟云学术

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

Published:2024-04-09 Issue:6 Volume:69 Page:2165-2174
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

van Linschoten Reinier C. A.,Jansen Fenna M.,Pauwels Renske W. M.,Smits Lisa J. T.,Atsma Femke,Kievit Wietske,de Jong Dirk J.,de Vries Annemarie C.,Boekema Paul J.,West Rachel L.,Bodelier Alexander G. L.,Gisbertz Ingrid A. M.,Wolfhagen Frank H. J.,Römkens Tessa E. H.,Lutgens Maurice W. M. D.,van Bodegraven Adriaan A.,Oldenburg Bas,Pierik Marieke J.,Russel Maurice G. V. M.,de Boer Nanne K.,Mallant-Hent Rosalie C.,ter Borg Pieter C. J.,van der Meulen-de Jong Andrea E.,Jansen Jeroen M.,Jansen Sita V.,Tan Adrianus C. I. T. L.,van der Woude C. Janneke,Hoentjen Frank,

Funder

ZonMw

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10620-024-08410-z.pdf

Reference13 articles.

1. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.

2. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18:69-81.e3.

3. van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021;54:234–248.

4. van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT et al. Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. The Lancet Gastroenterology & Hepatology. 2023. https://doi.org/10.1016/S2468-1253(22)00434-4.

5. Steyerberg EW, Eijkemans MJ, Harrell FE, Habbema DF. Prognostic Modeling with Logistic Regression Analysis In Search of a Sensible Strategy in Small Data Sets. Med Decis Making 2001;21:45–56.